Carvedilol

Mechanism of action and pharmacodynamics

Carvedilol has a specific chemical structure. It is a racemic mixture of two enantiomers, each possessing its own pharmacological activity profile. The levorotatory S-enantiomer acts as a non-selective blocker, affecting $\beta_1$-, $\beta_2$-, and $\alpha_1$-adrenoceptors. The dextrorotatory R-enantiomer is capable of blocking exclusively $\alpha_1$-adrenoceptors. Overall, the total $\beta$-blocking effect of the drug is significantly stronger than its influence on $\alpha_1$-receptors.

By blocking $\alpha_1$-adrenoceptors, the medication causes peripheral vasodilation and a substantial decrease in total peripheral vascular resistance (TPVR). Its effect on cardiac $\beta_1$-adrenoceptors naturally leads to a decrease in heart rate (HR), reduced myocardial contractility, and a drop in cardiac output.

Among the neurohormonal effects, the drug's ability to reduce renal renin secretion stands out. Additionally, the release of norepinephrine from sympathetic nerve terminals is suppressed due to the blockade of presynaptic $\beta_2$-receptors.

Distinctive properties and metabolism

The hemodynamic profile of the drug compares favorably with classical representatives of other groups:

• Unlike the use of selective $\beta$-adrenoceptor blockers, carvedilol therapy leads to a decrease in blood pressure without an initial increase in TPVR.
• Unlike isolated $\alpha$-adrenoceptor blockers, vasodilation is not accompanied by reflex tachycardia.

The final complex effect consists of a harmonious reduction in both cardiac preload and afterload.

The drug possesses important metabolic advantages (for example, compared to propranolol). It reduces tissue insulin resistance, which has a favorable effect on carbohydrate metabolism. The lipid profile during therapy improves due to a pronounced anti-atherogenic effect: the concentrations of triglycerides and low-density lipoproteins (LDL) decrease, while the level of high-density lipoproteins (HDL) increases.

Additionally, the molecule exhibits intrinsic antioxidant activity. Notably, even with prolonged use of the drug, there is no increase in the density (number) of $\beta_1$-adrenoceptors in myocardial tissues.

Clinical application and cardioprotection

In clinical practice, the drug is prescribed orally once or twice a day. The main indications for use are:

1. Hypertension.
2. Angina pectoris.
3. Moderate chronic heart failure (CHF) (strictly as part of combination therapy).

The drug is of particular value in the management of CHF patients. It exerts a potent cardioprotective effect. It actively prevents cardiomyocyte death and inhibits hypertrophy and pathological remodeling of the myocardium. Compared to $\beta_1$-selective agents (such as bisoprolol or metoprolol), carvedilol provides a more pronounced reduction in excessive sympathetic stimulation. This effect is due to the blockade of presynaptic $\beta_2$-receptors, which critically decreases norepinephrine secretion.

Pharmacokinetics and safety profile

When administered orally, the molecule is rapidly and almost completely absorbed from the gastrointestinal tract. However, systemic bioavailability remains low at approximately 25%. This is explained by intensive presystemic elimination in the liver, to which the S-enantiomer is particularly susceptible. Due to its high lipophilicity, the substance rapidly penetrates various tissues and biological fluids of the body.

Metabolism occurs in the liver involving cytochrome P-450 isoenzymes (primarily CYP2D6 and CYP2C9). As a result, three active metabolites are formed that largely retain $\beta$-blocking activity. Due to the genetic polymorphism of enzyme systems (especially CYP2D6 for the R-enantiomer), pharmacokinetics exhibits marked interindividual variability. Elimination of the drug and its metabolites occurs predominantly via the bile. The half-life is 7–10 hours.

Side effects are closely related to the mechanism of action:

• Cardiovascular system: Blockade of $\alpha_1$-receptors can provoke orthostatic hypotension. The risk of syncope is particularly high after the first dose, so initiating treatment in the supine position is recommended. Blockade of $\beta_1$-receptors can cause bradycardia (less pronounced than with pure $\beta$-blockers).
• Smooth muscle: The effect on $\beta_2$-receptors carries the risk of increasing bronchial tone (posing a serious danger in bronchial asthma) and increasing intestinal tone and peristalsis with the potential development of diarrhea.
• CNS: High lipophilicity allows the drug to cross the blood-brain barrier, which can lead to manifestations such as depression and sleep disorders.

Class and exam questions

What else to study on this topic

• Genetic polymorphism of cytochrome P-450 (CYP2D6) and its effect on drug metabolism
• Mechanisms of presystemic elimination and hepatic clearance of adrenoceptor blockers
• Pathophysiology of orthostatic hypotension during α1-blocker intake
• Effect of molecular lipophilicity on blood-brain barrier permeability

Other topics in the section "Drugs Acting on Adrenergic Synapses"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.